ZLD
Director Trades
| Date | Director | Value |
|---|
Company News
Zelira Therapeutics’ diabetic nerve pain drug outperforms Pfizer’s Lyrica
Perth-based Zelira Therapeutics (ASX: ZLD) has confirmed its cannabinoid-based diabetic nerve pain drug ZLT-L-007 has outperformed Pfizer’s commercially-available medication Lyrica (Pregabalin) in a multi-arm, head-to-head, US-based clinical trial. Zelira partnered with Pennsylvania-based global contract research organisation Affinity Bio Partners to manage the trial which involved 60 subjects to evaluate the efficacy, safety and tolerability of […]
Drawbacks of the TGA’s cannabis changes for listed pot stocks
Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator’s endorsement of the weed as an effective therapy that should be more freely available to the ailing masses. But the path to the pharmacy is likely to be harder than they […]
Zelira Therapeutics targets arterial disease and diabetic illnesses with medicinal cannabis
Medical cannabis company Zelira Therapeutics (ASX: ZLD) has committed to a binding five-year agreement with US-based company Cardiovascular Solutions of Central Mississippi (CVSCM) to develop and commercialise products to treat symptoms associated with peripheral arterial disease (PAD) and diabetic neuropathies (DPN). PAD is a circulatory condition in which narrowed arteries reduce blood flow to the limbs and […]
Zelira Therapeutics reveals more positive results from medical cannabis trial to treat insomnia
Zelira Therapeutics (ASX: ZLD) has announced its Phase 1b/2a medicinal cannabis trial to treat insomnia has met both its primary and secondary endpoints. The company today confirmed it has received the final clinical report for the trial, which shows its proprietary cannabis formulation ZTL-101 has produced “statistically significant and dose responsive improvements” in Insomnia Severity […]
Zelira Therapeutics meets primary endpoints for medical cannabis trial to treat insomnia
Biopharmaceutical company Zelira Therapeutics (ASX: ZLD) has announced positive results from a “first of its kind” phase 1b/2a trial using medicinal cannabis to treat chronic insomnia. The results confirmed all 23 participants treated with Zelira’s proprietary and patented medicinal cannabis formulation ZLT-101 demonstrated “statistically significant improvement” in Insomnia Severity Index (ISI) scores compared to the […]
Health House Holdings to distribute Zelda Therapeutics’ medicinal cannabis throughout Australasia and UK
Zelda Therapeutics’ (ASX: ZLD) medicinal cannabis products will be distributed across Australasia and the United Kingdom under a new agreement with Health House Holdings Ltd. The agreement follows Zelda’s intent to launch its HOPE products into global markets in 2020, which comprises products that have been made to treat Autism Spectrum Disorder symptoms. Also included […]
Zelda Therapeutics granted approval to trial medicinal cannabis in tackling the opioid epidemic
Bio-pharmaceutical company Zelda Therapeutics (ASX: ZLD) has taken a decisive step towards mitigating the effects of the growing opioid epidemic that is gripping several Western countries including Australia and the US. Earlier today, Zelda announced that its phase 1 opioid reduction trial was formally approved by the St Vincent’s Hospital Ethics and Governance Committees. The […]
Zelda Therapeutics broadens pancreatic cancer research as precursor to human trials
Zelda Therapeutics (ASX: ZLD) and West Australian-based Curtin University have broadened their pancreatic cancer research program to focus on in vivo animals when investigating the effect of Zelda’s medicinal cannabis-based formulations in conjunction with existing chemotherapy drugs. The pre-clinical pancreatic cancer study will explore the impact of a range of Zelda’s formulations with Abraxane and […]
SUDA Pharmaceuticals and Zelda Therapeutics to develop novel medicinal cannabis oral spray
Drug delivery specialist company SUDA Pharmaceuticals (ASX: SUD) has unveiled a deal with Zelda Therapeutics (ASX: ZLD) in the form of a fully funded feasibility and option agreement. The agreement will see the two companies work in partnership to develop an oral spray capable of utilising “pharmaceutical-grade cannabinoid derivatives” to treat various ailments such as multiple […]
Zelda Therapeutics commences its ‘pioneering’ insomnia trial using cannabis
Dual-listed biopharma company Zelda Therapeutics (ASX: ZLD) has kicked off its “pioneering” insomnia trial by dosing its first patient which it says represents a starting point for a wave of research and development that could well spill over into treatments being developed for other ailments. The trial will be conducted by the University of Western […]